Analytical data for patients with aPT antibodies
| aPT IgG, GAU/mL . | LAC titer, AU/mL . | β2GPI IgG, GAU/mL . | TEC . | sP-selectin, ng/mL . | FVII, % . | OAC INR . |
|---|---|---|---|---|---|---|
| 99.4 | 200 | 134.2 | Yes | 94 | 34 | 2.4 |
| 56.1 | 44 | 128.6 | Yes | 163 | 82 | < 1.5 |
| 40.5 | 30 | 118 | Yes | 66 | 93 | < 1.5 |
| 36.1 | 20 | 3 | No | 79 | 99 | None |
| 11.6 | 99 | 160.6 | Yes | 76 | 108 | None |
| 8.1 | 20 | 147.3 | Yes | 172 | 155 | None |
| 5.9 | 46 | 122.1 | Yes | 184 | 69 | None |
| 5.8 | 15 | 5.8 | Yes | 90 | 108 | None |
| 5.3 | 38 | 150.9 | Yes | 127 | 52 | 1.9 |
| 5.1 | 22 | 4.5 | Yes | 129 | 77 | None |
| 10.2 | 23 | 0 | Yes | 118 | 146 | < 1.5 |
| 5.9 | 21 | 0 | Yes | 90 | 87 | None |
| 5.9 | 9 | 0.4 | No | 111 | 103 | None |
| aPT IgG, GAU/mL . | LAC titer, AU/mL . | β2GPI IgG, GAU/mL . | TEC . | sP-selectin, ng/mL . | FVII, % . | OAC INR . |
|---|---|---|---|---|---|---|
| 99.4 | 200 | 134.2 | Yes | 94 | 34 | 2.4 |
| 56.1 | 44 | 128.6 | Yes | 163 | 82 | < 1.5 |
| 40.5 | 30 | 118 | Yes | 66 | 93 | < 1.5 |
| 36.1 | 20 | 3 | No | 79 | 99 | None |
| 11.6 | 99 | 160.6 | Yes | 76 | 108 | None |
| 8.1 | 20 | 147.3 | Yes | 172 | 155 | None |
| 5.9 | 46 | 122.1 | Yes | 184 | 69 | None |
| 5.8 | 15 | 5.8 | Yes | 90 | 108 | None |
| 5.3 | 38 | 150.9 | Yes | 127 | 52 | 1.9 |
| 5.1 | 22 | 4.5 | Yes | 129 | 77 | None |
| 10.2 | 23 | 0 | Yes | 118 | 146 | < 1.5 |
| 5.9 | 21 | 0 | Yes | 90 | 87 | None |
| 5.9 | 9 | 0.4 | No | 111 | 103 | None |
Antiprothrombin (aPT) immunoglobulin G (IgG) antibody titers (cutoff calculated as the 99th percentile = 1.8 IgG arbitrary units [GAU]/mL) in comparison to corresponding Lupus anticoagulants (LAC) titer and anti-β2-glycoprotein I (anti-β2GPI) IgG antibody titer. Further shown are corresponding soluble P-selectin (sP-selectin) and factor VII (FVII) levels for these patients (n = 13). The relation with occurrence of thromboembolic complications (TECs; yes or no) and the use of oral anticoagulants (OACs) is indicated, further documented by the International Normalized Ratio (INR), when affirmative. Patients are subdivided into 2 groups: patients with high LAC and simultaneously high anti-β2GPI IgG titer (n = 10) and patients with low LAC and/or low anti-β2GPI IgG titer (n = 3).